FindTrial
Sign In

EFFICACY AND SAFETY OF NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK CANCER (HNC) PATIENTS - JAPANESE REAL-WORLD DATA THROUGH CLINICAL CHART REVIEW -

EFFICACY AND SAFETY OF NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK CANCER (HNC) PATIENTS - JAPANESE REAL-WORLD DATA THROUGH CLINICAL CHART REVIEW - - - JAPANESE REAL-WORLD DATA THROUGH CLINICAL CHART REVIEW -

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000032600
Enrollment
500
Registered
2018-05-15
Start date
2018-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HEAD AND NECK CANCER

Interventions

None listed

Sponsors

Bristol-Myers Squibb Ono Pharmaceutical CO.,LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Recurrent/metastatic HNC patients with disease progression on or after a platinum-based therapy treated with nivolumab at least once from 01-Jul-2017 through 31-Dec-2017

Exclusion criteria

Exclusion criteria: History of participation in any clinical trials prior- or post-nivolumab treatment

Design outcomes

Primary

MeasureTime frame
Summary statistics for continuous outcomes will include mean, standard deviation, median,inter-quartile range, and range. Summary statistics for categorical or ordinal outcomes will include frequency and percentage. The primary analysis includes a description of actual usage of nivolumab and assessment of effectiveness and safety in which pre-specified immune-related adverse events (irAEs) identified—

Countries

Japan

Contacts

Public ContactJumpei Kamimito

Mebix, Inc Oncology Group

headneck@mebix.co.jp03-4362-4504

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026